Genetic Variants in the SCN9A Gene are Detected in a Minority of Erythromelalgia Patients
Acta Dermato-Venereologica · 2025
DOI: 10.2340/actadv.v105.42022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Dermato-Venereologica, 2025. Verfasst von Mari Skystad Kvernebo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Aleris Medical Center, Stømmen, Norway. mari.kvernebo@gmail.com. Hauptthemen laut MEDLINE: Erythromelalgia, NAV1.7 Voltage-Gated Sodium Channel, Gain of Function Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Gain-of-function variants in the voltage-gated sodium channel Nav1.7, encoded by the SCN9A gene, have previously been identified in patients with erythromelalgia, a clinical diagnosis defined by intermittent attacks of painful, hot, swollen, and red skin, predominantly involving the hands and feet. Symptoms are induced or aggravated by warming and relieved by cooling. In primary erythromelalgia there is no known underlying disease. This study investigated the frequency of SCN9A variants in a cohort of primary erythromelalgia patients collected at a single centre, and examined the clinical signs and symptoms associated with identified variants. One hundred patients with possible erythromelalgia were collected prospectively and evaluated by clinical examination. Thirty-five patients fulfilling the clinical criteria of primary erythromelalgia were screened for variants in SCN9A. Five were found to carry likely causal variants, including a variant found in 2 related individuals and a variant not previously described in patients with erythromelalgia. The clinical findings differed significantly between the patients. Overall, in this cohort only 4/34 (11.7%) of unrelated patients had erythromelalgia likely caused by gain-of-function variants in SCN9A. Variants in SCN9A are therefore likely to cause or contribute to primary erythromelalgia in only a small proportion of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Aleris Medical Center, Stømmen, Norway. mari.kvernebo@gmail.com.
- Xenon Pharmaceuticals Inc., Burnaby, Canada.
- Akershus Dermatology Centre, Lørenskog, Norway.
- Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Zitieren
APA
Skystad Kvernebo, M., Grayson, C., Stylianou, I. M., Woloshen, V., Radomski, C., Mørk, C., & Kvernebo, K. (2025). Genetic Variants in the SCN9A Gene are Detected in a Minority of Erythromelalgia Patients. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v105.42022
Vancouver
Skystad Kvernebo M, Grayson C, Stylianou IM, Woloshen V, Radomski C, Mørk C, et al. Genetic Variants in the SCN9A Gene are Detected in a Minority of Erythromelalgia Patients. Acta Dermato-Venereologica. 2025. doi:10.2340/actadv.v105.42022
BibTeX
@article{SkystadKvernebo2025,
author = {Skystad Kvernebo, Mari and Grayson, Celene and Stylianou, Ioannis M and Woloshen, Virginia and Radomski, Christopher and Mørk, Cato and Kvernebo, Knut},
title = {Genetic Variants in the SCN9A Gene are Detected in a Minority of Erythromelalgia Patients},
journal = {Acta Dermato-Venereologica},
year = {2025},
doi = {10.2340/actadv.v105.42022}
}
EUVIMED